ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases
{{output}}
ABT-874, a fully human mAb that blocks the binding of IL-12 and IL-23 to their shared IL-12 receptor beta1, is currently being developed by Abbott Laboratories for the potential treatment of Crohn's disease and psoriasis. The compound is currently in phase III... ...
